Biocartis Group NV
Develops and commercializes an automated molecular diagnostics platform for oncology.
BCART | BR
Overview
Corporate Details
- ISIN(s):
- BE0974281132 (+1 more)
- LEI:
- 549300J4HOJL5KG8HY54
- Country:
- Belgium
- Address:
- GENERAAL DE WITTELAAN 11 BOÎTE B, 2800 MECHELEN
- Website:
- https://www.biocartis.com/en
- Sector:
- Manufacturing
Description
Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-11-14 17:40 |
221114 PR EGM 2 Outcome_NL_FINAL.pdf
|
Dutch | 76.9 KB | ||
| 2022-10-28 07:00 |
EGM 2022 - 1L Audit Report (NL) - Signed.pdf
|
Dutch | 1.6 MB | ||
| 2022-10-28 07:00 |
EGM 2022 - 1L Receivables Board Report (NL).pdf
|
Dutch | 290.1 KB | ||
| 2022-10-28 07:00 |
Carens EGM - Proxy (ENG-DUT).pdf
|
Dutch | 379.1 KB | ||
| 2022-10-28 07:00 |
EGM 2022 - Rights Offering Board Report (NL).pdf
|
Dutch | 276.5 KB | ||
| 2022-10-28 07:00 |
EGM 2022 - CB Audit Report (NL) - Signed.pdf
|
Dutch | 556.6 KB | ||
| 2022-10-28 07:00 |
Carens EGM 2022 - Overview Voting Rights (ENG-DUT).pdf
|
Dutch | 52.9 KB | ||
| 2022-10-28 07:00 |
Carens EGM 2022 - Attendance Form (ENG-DUT).pdf
|
Dutch | 93.5 KB | ||
| 2022-10-28 07:00 |
Carens EGM - Vote by Letter Form (ENG-DUT).pdf
|
Dutch | 368.5 KB | ||
| 2022-10-28 07:00 |
EGM 2022 - CB Board Report (NL).pdf
|
Dutch | 3.0 MB | ||
| 2022-10-28 07:00 |
Carens EGM 2022 - Convening Notice (NL).pdf
|
Dutch | 208.1 KB | ||
| 2022-10-28 07:00 |
221027 PR EGM Carens_Convening notice_ENG_FINAL.pdf
|
English | 83.9 KB | ||
| 2022-10-28 07:00 |
EGM 2022 - Rights Offering Audit Report (NL) - Signed.pdf
|
Dutch | 554.9 KB | ||
| 2022-10-28 07:00 |
221027 PR EGM Carens_Convening notice_NL_FINAL.pdf
|
Dutch | 69.7 KB | ||
| 2022-10-28 07:00 |
221027 PR Conversion 1L_ENG_FINAL.pdf
|
English | 112.2 KB |
Automate Your Workflow. Get a real-time feed of all Biocartis Group NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biocartis Group NV
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biocartis Group NV via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-04-29 | Devogelaere Benoit | Executive member | Buy | 15,000 | N/A |
| 2021-04-28 | Marcofin BV | Executive member | Buy | 30,000 | N/A |
| 2021-04-27 | Herman Verrelst | Board | Buy | 60,000 | N/A |
| 2020-11-13 | Devogelaere Benoit | Executive member | Buy | 50,000 | N/A |
| 2020-05-06 | Herman Verrelst | Board | Buy | 50,000 | 249,625.00 EUR |
| 2020-05-06 | Herman Verrelst | Board | Buy | 300,000 | N/A |
| 2020-05-04 | Herman Verrelst | Board | Buy | 46,803 | 231,656.00 EUR |
| 2020-05-04 | Herman Verrelst | Board | Buy | 3,197 | 15,315.00 EUR |
| 2019-12-18 | Devogelaere Benoit | Executive member | Buy | 50,000 | N/A |
| 2019-12-16 | Welten Ewoud | Executive member | Buy | 10,000 | N/A |
Peer Companies
